Predictive quality assurance for linear accelerator target failure using statistical process control.


Journal

Biomedical physics & engineering express
ISSN: 2057-1976
Titre abrégé: Biomed Phys Eng Express
Pays: England
ID NLM: 101675002

Informations de publication

Date de publication:
03 08 2023
Historique:
received: 15 03 2023
accepted: 12 07 2023
medline: 4 8 2023
pubmed: 13 7 2023
entrez: 12 7 2023
Statut: epublish

Résumé

The performance of a linear accelerator (Linac) depends on the integrity of its x-ray target. The sudden failure of its target not only breaks down the Linac but also could contribute significant disruptions to patient care. This work is to develop a predicative quality assurance (QA) method using Statistical Process Control (SPC) and AutoRegressive Integrated Moving Average (ARIMA) modeling to identify the risk of target failure before it occurs. In the past years, we observed two incidents of target failure among our Linacs. Retrospectively, we collected past daily QA data (from both open fields and enhanced dynamic wedge (EDW) measurements) and analyzed its historical trend using methods of SPC and ARIMA. SPC is a technique that monitors process performance based on statistical analysis. ARIMA is a time-series forecasting algorithm that can be used to estimate future values based on its past pattern. Both have been evaluated for predictive QA in radiotherapy. Application of SPC on open beam QA data would not yield an early warning signal to the pending target failures. However, when the same SPC methodology applies to EDW measurements, the control limits were breached a couple of weeks before the target failed. EDW mechanism introduces nonuniform magnification factors over its wedge-directed beam profiles and is responsible for the sensitivity of its profile to changing beam properties induced by a degrading target. Further extension of the warning period may be possible by using ARIMA modeling. Predicative QA for EDW daily data using SPC and ARIMA methods may provide an early QA warning to incoming Linac target failure.

Identifiants

pubmed: 37437550
doi: 10.1088/2057-1976/ace6a1
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2023 IOP Publishing Ltd.

Auteurs

Jingdong Li (J)

Memorial Sloan-Kettering Cancer Center at Basking Ridge, NJ, United States of America.

Dongxu Wang (D)

Memorial Sloan-Kettering Cancer Center at Basking Ridge, NJ, United States of America.

Maria Chan (M)

Memorial Sloan-Kettering Cancer Center at Basking Ridge, NJ, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH